NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a phase 1 clinical trial conducted by researchers from the NIH. The candidate vaccine was co-developed NIAID and GlaxoSmithKline. November 28, 2014